At what enterprise value was UNIVERSITY COMPOUNDING PHARMACY (UCP) acquired in 2026?

During the acquisition of UNIVERSITY COMPOUNDING PHARMACY (UCP) by FAGRON in 2026, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 20M - 50M USD. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of UNIVERSITY COMPOUNDING PHARMACY (UCP) when it was acquired by FAGRON?

The exact EV/EBITDA multiple for UNIVERSITY COMPOUNDING PHARMACY (UCP) is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

What was the revenue of UNIVERSITY COMPOUNDING PHARMACY (UCP) at the time of the deal?

The revenue of UNIVERSITY COMPOUNDING PHARMACY (UCP) at the time of the deal is estimated to be in the range of 10M - 30M USD. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the UNIVERSITY COMPOUNDING PHARMACY (UCP) acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the UNIVERSITY COMPOUNDING PHARMACY (UCP) deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://markets.ft.com/data/announce/detail?dockey=1330-1001158717en-1B3FQAAFG7TUB0KPA2GMM0ROJ0

← DATABASE

Home Database Healthcare & PharmaUNIVERSITY COMPOUNDING PHARMACY (UCP)

01/2026

UNIVERSITY COMPOUNDING PHARMACY (UCP) acquired by FAGRON

UNITED STATES Life Sciences / Pharma & Biotech / Compounding EV 20M - 50M USD

Context

Fagron acquired 100% of University Compounding Pharmacy for an Enterprise granting to Fagron a stronghold in California (a high-barrier market) and adds complementary therapeutic expertise (Urology) to its existing US portfolio (which includes Anazao). Fagron expects to realize significant synergies over the next 18-24 months by integrating UCP into its national platform.

UNIVERSITY COMPOUNDING PHARMACY (UCP), which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Based in San Diego, UCP is a specialized 503A compounding pharmacy. Unlike 503B facilities (which manufacture in bulk for hospitals), 503A pharmacies prepare patient-specific medications prescribed by doctors. UCP has built a strong niche in the "Health & Wellness" segment, with specific leadership in Urology (e.g., erectile dysfunction treatments) and Hormone Replacement Therapy (HRT). It operates in California, a state with notoriously strict pharmacy regulations, making its license and clean compliance record a valuable asset. The company generates annual revenues of around $25 million.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
02/2026	NORD HOLDING	HALLMARQ VETERINARY IMAGING	UNITED KINGDOM	Life Sciences	NORD Holding have acquired Hallmarq Veterinary Imaging from August Equity to merge it with German-based OR Technology. The transaction establishes a new, globally active imaging technology holding company in the veterinary sector
02/2026	IMA GROUP	PROSYS	IRELAND	Life Sciences	IMA Group acquired a majority stake in ProSys Sampling Systems Limited from its co-founder and Treysa Limited. The transaction is a core component of IMA's international growth strategy, aiming to strengthen its "IMA Life" division by integrating specialized containment and sampling expertise
01/2026	YOTTA CAPITAL	VILLARD	FRANCE	Life Sciences	Yotta Capital Partners led a majority buyout of Villard, succeeding the previous sponsorless structure held by CEO. The transaction values the company on a solid growth trajectory, with the management team and historical regional partners reinvesting in the new pool
12/2025	CHARTERHOUSE	WINBACK	FRANCE	Life Sciences	Charterhouse Capital Partners acquired a majority equity stake in Winback following a competitive process that attracted interest from several top-tier private equity funds. This transaction facilitates the exit of Capza, which had supported the company since late 2021 through a minority "flex equity" structure, and allows the founding duo to cash out a portion of their holdings while reinvesting to remain significant minority shareholders and operational leaders
11/2025	PFIZER	METSERA	UNITED STATES	Life Sciences	Pfizer has finalized the acquisition of Metsera, an operation designed to fundamentally transform the group’s Internal Medicine portfolio and secure a leading foothold in the obesity treatment sector. The strategic rationale for this transaction centers on a "pipeline-transformation" play, merging the target's highly differentiated clinical-stage obesity candidates with the group's global development and commercial infrastructure
11/2025	ANJAC BEAUTY & HEALTH	HEALTH CHAIN GROUP (HCG)	SLOVENIA	Life Sciences	Anjac acquired a majority stake in HCG to accelerate its growth in the nutraceutical space. This is the 17th company to join the Anjac ecosystem. Beyond the acquisition cost, Anjac has committed to a EUR25M investment plan to expand the Velenje production site, aiming to triple its output within 12 months
11/2025	ARLANE	DESSINTEY	FRANCE	Life Sciences	Arlane has acquired a majority stake (approximately two-thirds) in Dessintey through a primary LBO. The transaction allows for the exit of early-stage investors Turenne Sante (via Relyens Innovation Sante) and Credit Agricole Haute-Loire, who invested in 2019
10/2025	PUBLIC MARKETS (IPO)	OTTOBOCK	GERMANY	Life Sciences	Ottobock successfully completed its Initial Public Offering on the Frankfurt Stock Exchange, marking the largest German IPO of 2025. The shares were priced at €66.00, with the first trading price reaching €72
09/2025	CAPVEST PARTNERS	STADA	GERMANY	Life Sciences	CapVest Partners agreed to acquire a controlling majority stake in Stada from Bain Capital and Cinven. This deal serves as an alternative to a planned IPO in Frankfurt, which was shelved due to market volatility
09/2025	INVESTCorporate	DCC HEALTHCARE	UNITED KINGDOM	Life Sciences	InvestIndustrial finalized the acquisition of DCC Healthcare Limited from the London-listed group DCC plc. This transaction is a strategic corporate carve-out designed to simplify DCC plc's operations, allowing the group to focus resources on its largest and most profitable Energy division

REFERENCES

Valuation range: EV 20M - 50M USD

Revenue range: 10M - 30M USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of UNIVERSITY COMPOUNDING PHARMACY (UCP) by FAGRON are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).